多模式干预对接受新辅助治疗的乳腺癌患者的影响:多模式项目研究方案
Amelia Muñoz-Lerma1, Rocío Sánchez-Sánchez2, Julia Ruiz-Vozmediano3
1Servicio de Oncología Médica, Hospital Universitario Virgen de las Nieves, 18004 Granada, Spain.
Contemporary clinical trials
|June 5, 2024
概括
这项研究调查了多模式干预,包括营养变化和体育炼,如何影响接受新辅助化疗的乳腺癌患者. 该干预旨在改善生活质量和治疗结果.
科学领域:
- 在瘤学瘤学.
- 临床营养学 临床营养学
- 运动生理学 运动生理学
背景情况:
- 接受新辅助化疗的乳腺癌患者经常经历生活质量下降和潜在的治疗并发症.
- 在新辅助化疗期间优化患者的福祉和治疗疗效对于改善瘤治疗结果至关重要.
研究的目的:
- 评估多模式干预 (营养行为改变和体育炼) 对乳腺癌患者的生活质量,化疗反应和耐受性的影响.
- 评估干预对瘤组织病理学,人体组成和生物化学参数的影响.
- 将这些结果与接受标准护理的对照组进行比较.
主要方法:
- 一项随机临床试验,涉及80名年龄在18至70岁的乳腺癌患者,接受新辅助化疗.
- 参与者将被随机分配 (1:1) 进入干预组 (营养行为改变和体育炼) 或对照组.
- 包括生活质量,化疗反应和耐受性,瘤组织病理学,身体组成和生物化学标志物的结果将在治疗前和治疗后进行评估.
主要成果:
- 将收集和分析主要结果 (生活质量) 和次要结果 (化疗反应,耐受性,瘤组织病理学,身体组成) 的数据.
- 将对血液参数进行探索性分析,包括生化,炎症和瘤标志物.
- 该研究旨在提供有关干预有效性的定量数据.
结论:
- 这项研究将阐明在新辅助化疗期间对乳腺癌患者实用的多模式干预措施的影响.
- 这些发现预计将对支持性癌症护理产生重大科学和临床影响.
- 这种干预在现实环境中的可行性表明了广泛临床应用的潜力.
相关概念视频
02:43Mouse Models of Cancer Study
Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...